A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2012
At a glance
- Drugs Tremelimumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 06 Jun 2012 Additional company (AstraZeneca) added in association as reported by ClinicalTrials.gov.
- 22 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History